International Stem Cell director plans sale of up to 32.8K shares

A director of International Stem Cell CORP filed a Rule 144 notice to potentially sell 32,802 equity-compensation shares held in a family trust.

Rhea-AI Filing Summary

International Stem Cell CORP (ISCO) is the issuer for which director Paul V. Maier has filed a notice of proposed sale of common stock under Rule 144. The notice covers up to 32,802 common shares, all acquired as stock grants under equity compensation programs.

The shares were granted over a period from September 20, 2014 through June 15, 2017, and Maier reports that no cash was paid to acquire them. The shares to be sold are held in the Paul V. & Shirley D. Maier Family Trust and are custodied at Charles Schwab Corp., with trading indicated on the OTC market.

Key Figures

Shares covered by Rule 144 notice: 32,802 shares Acquisition period start: September 20, 2014 Acquisition period end: June 15, 2017 +2 more

5 metrics

Shares covered by Rule 144 notice 32,802 shares Common stock of International Stem Cell CORP proposed for sale

Acquisition period start September 20, 2014 Beginning of period when the 32,802 shares were granted

Acquisition period end June 15, 2017 End of period when the 32,802 shares were granted

Date of Rule 144 notice September 11, 2026 Filing date for the notice of proposed sale

Security type Common stock International Stem Cell CORP common shares held at Charles Schwab Corp.

Key Terms

Rule 144, equity compensation, stock grants, OTC

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

equity compensation financial

"all part of stock grants as part of equity compensation."

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

stock grants financial

"all part of stock grants as part of equity compensation."

OTC market

"8004389 | 09/11/2026 | OTC"

OTC stands for "over-the-counter" and describes securities that trade directly between dealers or via dealer networks rather than on a formal stock exchange. It matters to investors because OTC listings typically have fewer reporting rules and lower trading volume, which can mean higher price swings, limited liquidity, and greater difficulty buying or selling shares—similar to shopping at a small flea market instead of a large, regulated supermarket.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ISCO's Form 144 filing by Paul V. Maier disclose?

It discloses that director Paul V. Maier intends, under Rule 144, to potentially sell up to 32,802 shares of International Stem Cell CORP common stock that were received as stock grants for equity compensation and are held in the Paul V. & Shirley D. Maier Family Trust.

How many ISCO shares are covered by this Rule 144 notice?

The notice covers up to 32,802 shares of International Stem Cell CORP common stock. The filer states these shares were acquired as stock grants over time and that the client did not pay cash to acquire them.

When were the ISCO shares proposed for sale originally acquired?

The shares were acquired over a period from September 20, 2014 through June 15, 2017, all described as stock grants received as part of equity compensation from International Stem Cell CORP.

In whose account are the ISCO shares held for this Form 144 sale?

The shares are to be sold from the account of the Paul V. & Shirley D. Maier Family Trust, with custody at Charles Schwab Corp., as stated in the Rule 144 filing.

On what date was the ISCO Form 144 notice filed?

The date of notice is listed as September 11, 2026. That is when the intent to sell the 32,802 shares of International Stem Cell CORP common stock under Rule 144 was formally reported.

What type of consideration did the filer provide for the ISCO shares?

The filer states that the client did not pay for the 32,802 International Stem Cell CORP shares. They were acquired as stock grants as part of equity compensation between 2014 and 2017.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 12:45 PM EDT Accepted by SEC EDGAR 09/11/2026 - 12:45 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001182615
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	International Stem Cell CORP
SEC File Number	000-51891
Address of Issuer	9745 BUSINESSPARK AVENUE SAN DIEGO CALIFORNIA 92131
Phone	760-940-6383
Name of Person for Whose Account the Securities are To Be Sold	MAIER PAUL V
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab Corp. 3000 Schwab Way Westlake TX 76262	32802	11808.00	8004389	09/11/2026	OTC

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/30/2014	Stock Grants	Issuer			32802	09/30/2014	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Client acquired 32,802 shares over a period of time between 9/20/2014 thru 6/15/2017, all part of stock grants as part of equity compensation. Client did not pay for these shares Shares to be sold from account PAUL V & SHIRLEY D MAIER FAMILY TRUST
Date of Notice	09/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Paul V Maier
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)